Theratechnologies Inc
THTX3.160USD
0.000
Market hours （ET）Quotes delayed by 15 min
145.30MMarket Cap
LossP/E TTM
More Details of Theratechnologies Inc Company
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
Company Info
Ticker SymbolTHTX
Company nameTheratechnologies Inc
IPO dateDec 21, 1993
CEOMr. Paul Levesque
Number of employees94
Security typeOrdinary Share
Fiscal year-endDec 21
Address2015 Peel Street, 11th Floor
CityMONTREAL
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeH3A 1T8
Phone15143367800
Websitehttps://www.theratech.com/
Ticker SymbolTHTX
IPO dateDec 21, 1993
CEOMr. Paul Levesque
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Thomas Molson
Mr. Andrew Thomas Molson
Independent Director
Independent Director
137.50K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Independent Director
Independent Director
110.90K
--
Mr. Paul Levesque
Mr. Paul Levesque
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
72.80K
--
Mr. Frank A. Holler
Mr. Frank A. Holler
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
59.75K
--
Mr. John Leasure
Mr. John Leasure
Global Commercial Officer
Global Commercial Officer
51.25K
--
Ms. Dale Maccandlish Weil
Ms. Dale Maccandlish Weil
Independent Director
Independent Director
44.16K
--
Mr. Philippe Dubuc
Mr. Philippe Dubuc
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
15.75K
--
Dr. Christian Marsolais, Ph.D.
Dr. Christian Marsolais, Ph.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
14.82K
--
Mr. Jocelyn Lafond
Mr. Jocelyn Lafond
General Counsel, Company Secretary
General Counsel, Company Secretary
4.50K
--
Mr. Joseph P. Arena
Mr. Joseph P. Arena
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Thomas Molson
Mr. Andrew Thomas Molson
Independent Director
Independent Director
137.50K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Independent Director
Independent Director
110.90K
--
Mr. Paul Levesque
Mr. Paul Levesque
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
72.80K
--
Mr. Frank A. Holler
Mr. Frank A. Holler
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
59.75K
--
Mr. John Leasure
Mr. John Leasure
Global Commercial Officer
Global Commercial Officer
51.25K
--
Ms. Dale Maccandlish Weil
Ms. Dale Maccandlish Weil
Independent Director
Independent Director
44.16K
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
EGRIFTA
13.88M
72.87%
Trogarzo
5.17M
27.13%
By RegionUSD
Name
Revenue
Proportion
United States
19.05M
100.00%
Europe
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
EGRIFTA
13.88M
72.87%
Trogarzo
5.17M
27.13%
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Investissement Québec
19.83%
Soleus Capital Management, L.P.
10.44%
Nantahala Capital Management, LLC
5.27%
Morgan Stanley & Co. LLC
4.82%
AIGH Capital Management, LLC.
3.37%
Other
56.27%
Shareholders
Shareholders
Proportion
Investissement Québec
19.83%
Soleus Capital Management, L.P.
10.44%
Nantahala Capital Management, LLC
5.27%
Morgan Stanley & Co. LLC
4.82%
AIGH Capital Management, LLC.
3.37%
Other
56.27%
Shareholder Types
Shareholders
Proportion
Private Equity
23.20%
Hedge Fund
15.71%
Research Firm
5.11%
Investment Advisor/Hedge Fund
1.73%
Individual Investor
1.15%
Investment Advisor
1.14%
Bank and Trust
0.43%
Venture Capital
0.03%
Other
51.49%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
90
22.35M
48.61%
-1.02M
2025Q1
91
22.45M
48.83%
-1.34M
2024Q4
86
23.57M
51.25%
-895.81K
2024Q3
83
24.25M
52.74%
-40.47K
2024Q2
85
24.07M
52.35%
-127.35K
2024Q1
90
23.97M
52.12%
-218.82K
2023Q4
90
24.01M
52.22%
+1.91M
2023Q3
92
7.44M
30.84%
-1.19M
2023Q2
93
7.55M
31.28%
-1.05M
2023Q1
94
7.50M
31.54%
-1.18M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Investissement Québec
9.12M
19.83%
--
--
Apr 29, 2025
Soleus Capital Management, L.P.
4.80M
10.44%
-1.00
-0.00%
Apr 29, 2025
Nantahala Capital Management, LLC
2.42M
5.27%
-259.67K
-9.68%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.21M
4.82%
-59.37K
-2.61%
Mar 31, 2025
AIGH Capital Management, LLC.
1.75M
3.81%
-536.91K
-23.48%
Mar 31, 2025
Worth Venture Partners, LLC
576.93K
1.25%
-163.09K
-22.04%
Mar 31, 2025
National Bank of Canada
197.07K
0.43%
+4.94K
+2.57%
Mar 31, 2025
Molson (Andrew Thomas)
137.50K
0.3%
--
--
Apr 29, 2025
Svoronos (Dawn A)
110.90K
0.24%
--
--
Apr 29, 2025
Harbour Investments, Inc
96.11K
0.21%
+8.33K
+9.49%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
DFA Dimensional International Core Equity 2 ETF
0%
DFA Dimensional International Core Equity 2 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 20, 2023
Merger
4<1
Jul 20, 2023
Merger
4<1
Jul 20, 2023
Merger
4<1
Jul 20, 2023
Merger
4<1
Date
Type
Ratio
Jul 20, 2023
Merger
4<1
Jul 20, 2023
Merger
4<1
Jul 20, 2023
Merger
4<1
Jul 20, 2023
Merger
4<1
